{"entity":{"id":"tissue-factor-expression","kind":"biomarker","name":"Tissue factor expression","aka":["tissue factor","TF expression","F3 expression","tissue factor positive"],"tldr":"Tissue factor, the clotting trigger, is overexpressed on cervical and several other cancers. Tisotumab vedotin is labelled for cervical cancer without a tissue factor test.","summary":"Tisotumab vedotin (Tivdak) is a tissue factor-directed ADC labelled for recurrent or metastatic cervical cancer after chemotherapy (innovaTV 301); the label names tissue factor only as the target and no expression threshold was used in the trials. Its ocular toxicity mirrors mirvetuximab's and requires the same eye care.","asOf":"2026-09-23","links":[{"label":"TIVDAK prescribing information (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9fe3f32-4219-466e-acb9-3f609b4f4df1"}],"tags":["biomarker","surface-antigen","no-threshold"],"related":["folr1-expression","pd-l1-cps"],"cancers":["cervical","recurrent-metastatic-cervical-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tisotumab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"target":"tissue-factor","measurement":"ihc-score","scoringRule":{"text":"The label names the antigen in the drug's description but does not require it to be measured before treatment; no approval threshold exists for this readout.","quote":"TIVDAK is a tissue factor (TF)-directed antibody and microtubule inhibitor conjugate","source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9fe3f32-4219-466e-acb9-3f609b4f4df1","sourceLabel":"TIVDAK prescribing information (DailyMed)"},"thresholds":[],"tests":[],"assays":[],"companionDiagnostics":[],"forPatient":"No tissue factor test is done before tisotumab vedotin; the drug is given on the basis of the cancer type. Eye drops and regular eye checks are part of the treatment."},"route":"/biomarkers/tissue-factor-expression/","neighbours":{"biomarker":[{"id":"folr1-expression","kind":"biomarker","name":"Folate receptor alpha expression (FRα-positive, PS2+ >= 75%)","route":"/biomarkers/folr1-expression/"},{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"}],"drug":[{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/"}],"target":[{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/"}]}}